A New Treatment for Severe Alopecia Areata Has Been Approved in the USA!
Learn about a new alopecia treatment in the US.
Concert Pharmaceuticals CTP‑543: Is a second FDA-approved treatment for alopecia areata on its way?
Concert Pharmaceuticals reports more positive topline results for CTP-543 as they prepare to submit for FDA approval in the first half of 2023. How exciting!
Concert Pharmaceuticals begins THRIVE-AA2 phase 3 clinical trial for JAK inhibitors (CTP-543)
CANAAF is thrilled to share that Concert Pharmaceuticals has announced the launching of THRIVE-AA2, the second planned Phase 3 clinical